Peter J. Hotez Quotes

There is an urgency to create vaccines for diseases which don't make money.

[V]accines are safe and cannot possibly cause autism...

We invite scientists from all over the world to come into our vaccine labs to learn how to make vaccines under a quality umbrella, whereas you cannot walk into Merck or GSK or Pfizer or Moderna and say, “Show me how to make a vaccine.” With our group, we can.... the biggest frustration was never really getting that support from the G7 countries... I going on cable news networks... trying to raise meager funds just to get started... fortunately, we were able to get some funding through Texas- and New York-based philanthropies, and...we raised about...$7 million...with that, we were able to pay our scientists to actually do this, transfer the technology, no patent, no strings attached, to India, now, as I said, Indonesia, Bangladesh and Botswana... we’ve been getting calls for help all over the world from ministries of science and ministries of health, and we do what we can. We could do a lot — I mean, if we had even a fraction of the support that, say, Moderna or the other pharma companies had gotten, who knows? We might have been able to have the whole world vaccinated by now.... It’s even a vegan vaccine... So, now our partners in Indonesia... are trying to do this as a halal vaccine for Muslim-majority countries, which is pretty exciting, as well.

[I]n Houston (and elsewhere in Texas) is an area known as the Fifth Ward... Driving... deep into this neighborhood reminded me of the terrible poverty I had seen... in destitute areas of Honduras, Guatemala, Brazil, and China. I saw... images... just like the standard global disease movie typically shown to first-year public health or medical students. ...It was even more astonishing when we turned our global health lens inward to study diseases that were infecting impoverished areas... [W]e found widespread NTDs... in Texas and elsewhere in the southern United States. ...NTDs are first and foremost diseases of acute poverty. ...[W]e determined that 12 million Americans who live at such poverty levels suffer from at least one NTD. The diseases include neglected parasitic infections such as , , , and .

In 2006, I became founding editor in chief of PLOS Neglected Tropical Diseases, a then new journal for a growing community of scientists and public health officials committed to studying the (NTDs). ...I became deeply impressed with the number of papers reporting on disease findings in middle-income countries, and even in some high-income countries. This... combined with my personal experiences after moving to Texas and seeing first-hand the endemic tropical diseases, inspired me to look more deeply into the health disparities of the poor who live in the midst of wealth. ...Many of the findings in this book are based on data and information published in [the journal].

The big pharma companies are still not going in. Some of the biotechs are starting to, because they're trying to really accelerate their technology... and hopefully to flip it around for something else that will make money. We need a new system in place.

In 2011, together with a team of 15 scientists, I relocated to Houston, Texas, to launch a new school devoted to poverty-related diseases. The National School of Tropical Medicine at is a joint venture among three biomedical institutions—Baylor, , and the —with a mission devoted to research on and training in the treatment of neglected tropical diseases, or NTDs...

[W]e took this on... with the idea of pioneering not only interest in science, but also a new business model, and the business model part, we haven't quite figured out yet, because we're trying to make... vaccines for diseases no one else will make.

[H]ad we had those investments early on, to carry this all the way through clinical trials years ago, we could have had a vaccine ready to go.

So we have a vaccine now in clinical trials, a vaccine that we hope will advance to the clinic soon, a Hookworm vaccine in clinical trials, a new vaccine that's moving into the clinic. I like to say that these are the most important diseases that you've never heard of. These are some of the most common afflictions of the world's population, but they mostly occur among people who live in extreme poverty... [S]o there is no model to figure out who's going to pay for them. So as a consequence, neither the biotechs nor the big pharmaceutical companies make those vaccines.

There's still no road map for what you do to make a vaccine in the midst of a devastating public health outbreak.

But we collaborated with a unique group that figured out how to solve the problem. That if you narrow it down to the smallest subunit, the piece that... [is] called the receptor binding domain, that docs with the receptor, you get protection, and you don't get that immune enhancement phenomenon. ...We proposed this to the . They funded it and we wound up actually making and manufacturing, in collaboration with , a first generation SARS vaccine. So SARS was the one that emerged in 2003... and then this new one... we call the SARS 2 Coronavirus. We had it manufactured, but then we could never get the investment to take it beyond that. ...We had the vaccine ready to go, but we couldn't move it into the clinic, because of lack of funding, because by then nobody was interested in Coronavirus vaccines.

I perceive... a dearth of voices speaking out against the modern anti-vaccination movement. Their false claims and public statements more often than not go unchallenged. I hope that this book might serve as a clarion call for other scientists and physicians to speak out on behalf of science.

Today, the NTDs represent the most common afflictions of people who live in extreme poverty. These ailments include diseases such as hookworm, , , and —or... the most important diseases you've never heard of. Virtually every impoverished individual is infected with at least one NTD.

[O]ne of the things that we're not hearing a lot about is the unique potential safety problem of Coronavirus vaccines. ...This was first found in the early 1960s with the respiratory syncytial virus [RSV] vaccines, and it was done here in Washington with the NIH and Children's National Medical Center... [S]ome of those kids that got the vaccine actually did worse, and I believe that there were two deaths in the consequence of that study. ...[W]hat happens with certain types of respiratory virus vaccines, you get immunized, and then when you get actually exposed to the virus you get this kind of paradoxical immune enhancement phenomenon. ...[I]t's a real problem for certain respiratory virus vaccines. That killed the RSV program for decades. Now the Gates Foundation is taking it up again, but when we started developing Coronavirus vaccines (and our colleagues) we noticed in laboratory animals, that they started to show some of the same immune pathology that resembled what had happened 50 years earlier.